Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Associate professor Stephen McFarlane. Drug not even worthy of having a full professor run it. He heads up a dementia facility that’s on every side of town in the us.
No stank you.
Soon. LOL. That’s the best we got. Soon. Fire misleading
It’s a $2 stock. Anyone can buy it. It’s not exclusive. If market believed it, the SP would be higher. It will continue to be a $2 stock and more than likely it will be sub $1 in time.
More than likely fail AD. If the news was good enrollment would be ahead of schedule. But expectations are low.
CEO promised North America site and can’t even get one up and running. That’s failure.
It’s not like Anavex share price is $1000 bucks a share and out of reach. It’s not like we missed the boat.
Missling is synonymous with over promise and under deliver.
Now he does not say anything worthwhile. SOON. LOL.
If company had a real board, he would be fired.
Wrong. A bunch of misdiagnosed patients like in every trial.
Anavex is not $1800 a share. It’s a $2 stock. If investors had any real interest, they would buy the stock. If there is value, investors will buy the stock at any price like Amazon. Right now the value is between $2 and $3. It’s not like if the price gets to $3.50 the price will be out of reach for anyone if their is real value.
Penny stock it is.
Anavex makes excuses as to the lack of progress and markets it as innovation. Spent years on Anavex plus and it failed, now this shiny object.
I disagree as two families I’m near are past 10 years.
Anavex is synonymous with failed leadership. They are trying to milk this 32 patient non placebo controlled trial for 5 years.
This story is old. Market is over it.
The developer of 2 73 sold drug for $6k a month to Anavex then developed a better molecule. Showed his confidence in this old molecule.
If duration in a subject is a component of success, BP would have cured, not slowed the decline of Alzheimer’s before Anavex was a printing company
Reply to
I’ll bet that MacFarlanes 32 all had AD !
He’s been in the business a long time
Lol. Australia is only place in the world were GPs don’t misdiagnosed Alzheimer’s.
Lol. Yeah. No one was misdiagnosed. Yeah. Sure.
https://nationalpost.com/news/world/the-pain-of-being-misdiagnosed-with-alzheimers-is-more-common-than-we-realize-doctors-say
I will refer to the article and other article outlining the GP doing the diagnoses.
Show me proof where none of the 32 were not misdiagnosed with Alzheimer’s. If one was misdiagnosed than it’s possible 8 were misdiagnosed equals Responders.
Anavex having problems recruiting in AD.
Trial is 450 patients. First patient dosed 8/28/18. Recruiting at 16 sites. Other sites enroll 7 to 10 patients. #1 site is at 31 goal is 50. Dr said recruiting will go into early 2021.
Math not adding up to 450.
Give #1 site 50 which is top end of goal.
Give the other 15 sites top end of their goal of 10 for 150 total.
That’s only 200 patients total.
Looks like we are 250 patients short and again Dr has already admitted recruiting in 2021.
Sorry this news is not good. Drs math is not adding up.
ANAVEX trial- A phase 2b/3, double-blind, randomised, placebocontrolled 48-week safety and efficacy trial of ANAVEX2-73 for the
treatment of Alzheimer’s disease
Associate Professor Macfarlane’s study team has been
involved in testing the ANAVEX2-73 molecule since 2014
and were heavily involved in writing and editing the
previous phase 2a, and current phase 2b/3, protocols.
ANAVEX2-73 is a novel compound that is thought to act on
the sigma 1 intracellular receptor.
Its mode of action is unique in that most (if not all) other
molecules developed thus far to treat Alzheimer’s Disease target
the removal of a single type of toxic protein (either beta amyloid
or Tau). In contrast, ANAVEX2-73 is thought to remove all forms of
misfolded proteins from brain cells.
While involved in the phase 2a study, Associate Professor
Macfarlane and his team saw positive (and at times drastic)
increases in cognition and functioning in study participants, and
are pleased to be involved in the phase 2b/3 study. The study will be
recruiting throughout 2019 and most likely 2020 and into early 2021.
Some key achievements of the HammondCare site in relation to
this study include:
1. Associate Professor Stephen Macfarlane has been appointed
as the global study lead for this study
2. The Malvern site was the first site in the world to be initiated
3. Ours is the global No.1 recruiting site (most sites average 7-10
patients per study, whilst Malvern already has 31 patients on
study and aims to recruit 40-50 patients)
4. This trial is currently being conducted at over 15 sites globally
and will run for another 24 months
“So a lot of people are just diagnosed by a GP without access to supports and advanced diagnostic skills and experience.”
This article is from Australia.
It’s possible that not one person out of 32 had Alzheimer’s. Not likely put possible.
That makes no sense.
Reply to
MacFarlane is also in charge of Hammondcare, a large non profit care facility..
Hence "associate" and not full professor.
There is no truth to the claim that participants in the P2a were misdiagnosed. MacFarlane helped to develop the following guidelines
https://www.australianageingagenda.com.au/2018/07/10/head-of-dementia-initiative-talks-to-ccr/
As of last summer recruitment took 3 years. States it in the article.
Trial is not important enough to have a professor lead it. One can get the title referenced by leading a memory care center popping up in every corner in America. More patient care facilities are popping up in every American major city and the Stephane’s of the world are leading them.
https://nationalpost.com/news/world/the-pain-of-being-misdiagnosed-with-alzheimers-is-more-common-than-we-realize-doctors-say
Some people were misdiagnosed in this trial.
And you take a place we’re GPs are allowed to diagnose ALZ.
This trial is not even important enough to have a full professor work on the trial. Stephane is and has been an associate professor and really the only ONE person responsible.
He will be the fall guy to take all the blame when this goes south.
We already posted articles about GP diagnoses in Australia.
In Australia a GP can diagnose Alzheimer’s, not a neurologist so misdiagnosed percent more than likely exceeds US. One reason to promise North America trial sites for AD and not deliver.
Add as many Australia participants ( Misdiagnosed) as possible and add North America sites as late as possible to make investors think results are significantly significant.
Keep lie alive and try to profit off of other indications.
AD trial will probably fail and hence the reason it got pushed to the back.
Penny flippers will show up in mass. End result will not be what everyone expects. Sell high and buy back in or short from high.
Reply to
Anyone who wants in is in already. Positions have been taken.
Only new money gets the SP up.
New money only comes in on new news.
Let’s get some!
Reasons to short from a SA article 2 years ago.
Anavex is trying to cure an intractable disease, and its competitors are formidable.
Anavex's trials have been too small to attach any efficacy significance.
Moreover its data has been inconsistent, shedding doubt on the science
Not much has changed.
We said HH was going to leave.
Reply to:
I still think there's something more to this than meets the eye. I believe the Hampel, Esai, Anavex tie up is alive and well.
Who doesn't want a piece of the next Keytruda?
It’s always good to add if losing money is the objective.
Misery loves company.
Reply to
Just add all you can!
Doesn’t investing aggressively in a stock that is going bankrupt tantamount to financial suicide?
What are the consequences to aggressively shorting a stock that is soon to be financially successful? I guess I just don’t understand the short investment
Smoke and mirrors. Give retail the perception of movement or progress. Ask Clint in IR. He’s always busy doing something close to nothing.
Reply to
I was thinking along these lines earlier. Why do you need SVP of clinical operations if you already have your trials up and running. Next quarter we have the Rett <18 trial beginning... Not much else immediately planned, so.....what's coming ... smile
As forecasted SP down even more. I wonder why investors are selling when everyone bought in at $1.25 or less.
$1.25 is the cost basis for all or below. I heard .18 cents this weekend.
This has nothing to do with the successor or failure of a trial. 2-73 can still fail trial.
The green Turned to red for the day. This stock is toast for a while.
No they won’t...
Anavex is using biomarkers and data that may not be understood by the public, or even many analysts.
Those biomarkers will gain credibility when regulatory agencies begin to weigh in on them in the context of the trials.
2-73 to cure world hunger I was told. Also a good sleeping pill.
The pump will be a new indication or publications like it will cure cancer. Oh yeah they already stated that. This is really a cure all drug with zero clinical control results. NOT.
Sometimes it’s what is not said.. For example, Misleading has not received his options for 50% enrollment for AD. So based upon what is not said AD is less than 50% enrolled.
Also it was documented by Mrs Misleading that enrollment would be near 3 patients a day. Wrong again. We would have near 700 patients enrolled.
Anavex CEO and others continue to mislead, conceal and publish half truths. Integrity matters.
Fire misleading and others. Poor representatives.